Analysis of patients who have already received Chemo & radiation for esophageal & gastroesophageal junction cancer

Completed

Conditions: Esophageal & Gastroesophageal cancer patients who have already received chemoradiation

Registration Number: CTRI/2014/07/004776

Lead Sponsor: Not Applicable

Brief Summary: At TMH, wetreat patients with locally advanced esophageal cancer of the upper thirdesophagus or CA involving the middle or lower third of the esophagus or GEjunction, that is not felt to be amenable to resection in the multidisciplinaryclinic, with definitive radical chemoradiotherapy. Patients with locallyadvanced esophageal or gastroesophageal junction cancer who have undergonesurgical resection, may also be advised adjuvant concurrent chemoradiotherapybased on various features in the histopathology report or based on decisionmade in the joint clinic.5

Since January2011, we have maintained a prospective database of patients treated withradical concurrent chemoradiotherapy. We wish to analyze this dataretrospectively.

We will include all patients who have receivedchemotherapy at Tata Memorial Hospital concurrently with radical radiotherapyfor esophageal and GE junction carcinoma, from January 2011 onwards (to date),whose data has been prospectively entered in a database that has beenmaintained in the medical oncology department at Tata Memorial Hospital.

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 200

Inclusion Criteria

We will include all patients who have received chemotherapy at Tata Memorial Hospital concurrently with radical radiotherapy for esophageal and GE junction carcinoma, from January 2011 onwards (to date), whose data has been prospectively entered in a database that has been maintained in the medical oncology department at Tata Memorial Hospital.

Exclusion Criteria

Not provided

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary objective:-	Acute toxicity weekly while on CTRT \| Then at 6 weeks after completion of CTRT \| Then every 3 months for first 2 years and \| At any point in between as needed.
To assess the toxicity of weekly Carboplatin and Paclitaxel in combination with radical radiotherapy in patients with esophageal and GE junction cancer.	Acute toxicity weekly while on CTRT \| Then at 6 weeks after completion of CTRT \| Then every 3 months for first 2 years and \| At any point in between as needed.

Secondary Outcome Measures

Name	Time	Method
Secondary objectives:-	1.Overall survival

Trial Locations

Locations (1): Tata Memorial Hospital
🇮🇳
Mumbai, MAHARASHTRA, India
Tata Memorial Hospital
🇮🇳Mumbai, MAHARASHTRA, India
Dr Vanita Noronha
Principal investigator
09769328047
vanita.noronha@gmail.com